Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:IMTX NASDAQ:VIR NASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.77-3.6%$3.82$1.94▼$6.51$1.51B1.028.81 million shs5.91 million shsIMTXImmatics$10.79-5.3%$10.44$4.30▼$12.41$1.53B1.31400,133 shs1.52 million shsVIRVir Biotechnology$9.33-0.7%$9.60$4.16▼$11.66$1.59B1.71.67 million shs1.22 million shsYMABY-mAbs Therapeutics$8.61$8.58$3.55▼$8.61$391.24M0.54637,200 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-3.64%-5.36%+30.33%+62.24%+127.14%IMTXImmatics-5.27%-6.26%-0.74%+8.99%+148.62%VIRVir Biotechnology-0.74%-9.33%+0.21%+21.01%+98.51%YMABY-mAbs Therapeutics0.00%0.00%0.00%0.00%+106.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.77-3.6%$3.82$1.94▼$6.51$1.51B1.028.81 million shs5.91 million shsIMTXImmatics$10.79-5.3%$10.44$4.30▼$12.41$1.53B1.31400,133 shs1.52 million shsVIRVir Biotechnology$9.33-0.7%$9.60$4.16▼$11.66$1.59B1.71.67 million shs1.22 million shsYMABY-mAbs Therapeutics$8.61$8.58$3.55▼$8.61$391.24M0.54637,200 shsN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-3.64%-5.36%+30.33%+62.24%+127.14%IMTXImmatics-5.27%-6.26%-0.74%+8.99%+148.62%VIRVir Biotechnology-0.74%-9.33%+0.21%+21.01%+98.51%YMABY-mAbs Therapeutics0.00%0.00%0.00%0.00%+106.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.71Moderate Buy$8.1771.21% UpsideIMTXImmatics 2.67Moderate Buy$19.0076.09% UpsideVIRVir Biotechnology 2.89Moderate Buy$20.25117.04% UpsideYMABY-mAbs Therapeutics 2.00Hold$9.5110.50% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, IMTX, ABCL, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/5/2026ABCLAbCellera Biologics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.004/28/2026IMTXImmatics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026ABCLAbCellera Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ABCLAbCellera Biologics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.004/9/2026ABCLAbCellera Biologics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/16/2026IMTXImmatics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.003/4/2026VIRVir Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.002/26/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.002/24/2026VIRVir Biotechnology BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$75.13M19.39N/AN/A$3.07 per share1.55IMTXImmatics$54.60M26.49N/AN/A$4.09 per share2.64VIRVir Biotechnology$68.56M22.95N/AN/A$4.82 per share1.94YMABY-mAbs Therapeutics$87.68M4.46N/AN/A$2.05 per share4.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.41M-$0.49N/AN/AN/A-181.75%-14.86%-10.62%N/AIMTXImmatics-$222.26M-$1.84N/AN/AN/A-572.35%-47.65%-39.46%N/AVIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%N/AYMABY-mAbs Therapeutics-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%N/ALatest YMAB, IMTX, ABCL, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/11/2026Q1 2026ABCLAbCellera Biologics-$0.22-$0.14+$0.08-$0.14$5.41 million$8.32 million5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 million2/24/2026Q4 2025ABCLAbCellera Biologics-$0.18-$0.03+$0.15-$0.03$6.31 million$44.85 million2/23/2026Q4 2025VIRVir Biotechnology-$0.42-$0.31+$0.11-$0.31$19.91 million$64.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A14.0511.32IMTXImmaticsN/A11.7211.72VIRVir BiotechnologyN/A7.117.11YMABY-mAbs TherapeuticsN/A4.003.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%IMTXImmatics64.41%VIRVir Biotechnology65.32%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.40%IMTXImmatics3.30%VIRVir Biotechnology16.00%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500305.38 million218.57 millionOptionableIMTXImmatics260134.07 million129.65 millionOptionableVIRVir Biotechnology580168.65 million141.67 millionOptionableYMABY-mAbs Therapeutics15045.44 million36.49 millionOptionableYMAB, IMTX, ABCL, and VIR HeadlinesRecent News About These CompaniesY-Mabs Therapeutics Completes Merger with Perseus BidCoSeptember 16, 2025 | tipranks.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?September 1, 2025 | zacks.comY-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comY-mAbs (YMAB) Q2 Revenue Falls 14%August 9, 2025 | aol.comAY-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2025 | zacks.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7, 2025 | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7, 2025 | businesswire.comY-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings CallAugust 7, 2025 | quiverquant.comQY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025August 7, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)August 7, 2025 | msn.comSERB bets on rare cancer drug in $412 million deal for Y-mAbsAugust 6, 2025 | thepharmaletter.comTJones Trading Downgrades Y-mAbs Therapeutics (YMAB)August 6, 2025 | msn.comYmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?August 6, 2025 | zacks.comShareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersAugust 5, 2025 | prnewswire.comY-mAbs stock soars after SERB Pharmaceuticals announces acquisitionAugust 5, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, IMTX, ABCL, and VIR Company DescriptionsAbCellera Biologics NASDAQ:ABCL$4.77 -0.18 (-3.64%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$4.80 +0.03 (+0.59%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Immatics NASDAQ:IMTX$10.79 -0.60 (-5.27%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$10.77 -0.02 (-0.19%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Vir Biotechnology NASDAQ:VIR$9.33 -0.07 (-0.74%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$9.40 +0.07 (+0.75%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Y-mAbs Therapeutics NASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
